Surveyed Physicians Will Continue to Use Singulair Regardless of March 2008 Suicidality Claim, According to a New Report from Decision Resources
December 1, 2008–Waltham, Mass.– Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline's Advair is declining in all lines of therapy for newly diagnosed asthma patients.
The new report entitled Treatment Algorithms in Asthma shows a reduction in Advair use in first-, second- and third-lines of therapy to 12.2 percent, 13.6 percent, and 14.6 percent, respectively when compared to the 2007 analysis that showed Advair was prescribed in 13.9 percent, 19.3 percent and 16.5 percent of first-, second- and third-line patients, respectively.
The decline in Advair’s patient share is due to several factors: physicians’ (particularly primary care physicians [PCPs]) increasing use of Merck’s Singulair first-line, pushing Advair to later lines of therapy; specialists favoring newer once-daily inhaled corticosteroids (ICSs) with more favorable side-effect profiles in patients with less-severe disease prior to progressing to a long-acting beta2agonist (LABA)/ICS combination; and physician movement towards using AstraZeneca’s newly launched Symbicort as an alternative to Advair in later lines of therapy.
The report also finds that surveyed physicians will continue to use Singulair first-line regardless of March 2008 media reports linking the drug to behavior/mood changes and suicidality (suicidal thinking and behavior).
“The majority of pulmonologists, allergists and PCPs we surveyed told us that these media reports have had no effect on their treatment practice,” added Dr. Westphal. “However, more surveyed allergists and PCPs told us that in the next two years they are likely to monitor their Singulair patients with increased vigilance, which likely reflects their treatment of a higher percentage of patients under the age of 18 compared with surveyed pulmonologists.”
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
About Decision Resources
Decision Resources ( www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
###
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.